DOI: 10.1055/s-00000094

Zeitschrift für Gastroenterologie

References

Berruti A. et al.
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differenziated neuroendocrine tumors: the XELBEVOCT study.

BMC Cancer 2014;
14: 184

Download Bibliographical Data

Search in:
Access: